title: Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma.
abstract: The aim of this study is to evaluate the clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with advanced laryngeal squamous cell carcinoma (LSCC). A total of 73 patients with advanced LSCC were retrospectively reviewed. Tumor sections were stained by immunohistochemistry for LAT1, 4F2hc, system ASC amino acid transporter-2 (ASCT2), cell proliferation by Ki-67, microvessel density (MVD) determined by CD34 and p53. A positive LAT1, 4F2hc and ASCT2 expression (staining more than a quarter) in the primary sites were recognized in 85, 80 and 45 %, respectively, and a high LAT1, 4F2hc and ASCT2 expression (staining more than a half) yielded 48, 31 and 18 %, respectively. High expression of LAT1 was significantly associated with lymph node metastasis, 4F2hc, ASCT2, Ki-67 and p53. The expression of LAT1 was significantly correlated with ASCT2, 4F2hc, cell proliferation, and MVD. By univariate analysis, there was no statistically significant relationship between LAT1 expression and prognosis in advanced LSCC. LAT1, 4F2hc and ASCT2 were highly expressed in patients with advanced laryngeal cancer. Our study suggests that the expression of LAT1 plays a crucial role in the metastasis and tumor progression in advanced LSCC.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, nikkuni@gunma-u.ac.jp.
authors.forename: Osamu
authors.initials: O
authors.lastname: Nikkuni
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Kaira
authors.forename: Minoru
authors.initials: M
authors.lastname: Toyoda
authors.forename: Masato
authors.initials: M
authors.lastname: Shino
authors.forename: Koichi
authors.initials: K
authors.lastname: Sakakura
authors.forename: Katsumasa
authors.initials: K
authors.lastname: Takahashi
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Tominaga
authors.forename: Noboru
authors.initials: N
authors.lastname: Oriuchi
authors.forename: Masami
authors.initials: M
authors.lastname: Suzuki
authors.forename: Misa
authors.initials: M
authors.lastname: Iijima
authors.forename: Takayuki
authors.initials: T
authors.lastname: Asao
authors.forename: Masahiko
authors.initials: M
authors.lastname: Nishiyama
authors.forename: Shushi
authors.initials: S
authors.lastname: Nagamori
authors.forename: Yoshikatsu
authors.initials: Y
authors.lastname: Kanai
authors.forename: Tetsunari
authors.initials: T
authors.lastname: Oyama
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Chikamatsu
mesh_terms: D000368:Aged; D026962:Amino Acid Transport System ASC / Q000235:genetics*; D026905:Amino Acid Transport Systems / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000473:pathology*; D049109:Cell Proliferation / Q000235:genetics; D005260:Female; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000473:pathology*; D006801:Humans; D027283:Large Neutral Amino Acid-Transporter 1 / Q000235:genetics*; D007822:Laryngeal Neoplasms / Q000235:genetics* / Q000473:pathology*; D008207:Lymphatic Metastasis / Q000235:genetics / Q000473:pathology; D008297:Male; D015778:Minor Histocompatibility Antigens; D009367:Neoplasm Staging / Q000379:methods; D011379:Prognosis; D012189:Retrospective Studies; D000077195:Squamous Cell Carcinoma of Head and Neck
chemical_list: D026962:Amino Acid Transport System ASC; D026905:Amino Acid Transport Systems; D014408:Biomarkers, Tumor; D027283:Large Neutral Amino Acid-Transporter 1; D015778:Minor Histocompatibility Antigens; C420506:SLC1A5 protein, human